1
|
Gaynon P, Honig GR. A Computer-Based System for Management of Clinical and Laboratory Data of a Comprehensive Sickle Cell Center. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1636150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Procedures have been established for the computer-assisted collection and retrieval of data generated in the screening and patient care functions of a comprehensive sickle cell center. Data are collected on preprinted mark sense forms from three encounters: hemoglobinopathy screening, outpatient clinic visits, and transfusions. Inpatient clinical data are organized following a prepared outline and are entered directly onto diskpack via a remote terminal. Corrections and verifications of all data entries are performed utilizing the editing capabilities of WYLBUR. Confidentiality of information is maintained by application of a password system for access to the data base and by procedures that assure security of tapes and diskpacks containing clinical and screening data.
Collapse
|
2
|
Abstract
An automated parsing routine was written for extracting the »site«, »diagnostic«, and »modifier« components of the diagnostic statements of the diagnostic summary of surgical pathology reports. Such parsed reports appear to be suitable for input into an information retrieval system for the surgical pathology reports.Data was input through a key-to-tape device producing a computer compatible magnetic tape with a record size of 870 bytes. The statements were parsed through syntactic and morphological analysis utilizing the common prepositions, the common punctuations and the morphemal constructions common in medical terms. (A total of sixty-two delimiters were used). Certain suffix transformations were performed, converting some »site« adjective to »site« nouns, and some »diagnostic« nouns to »site« nouns. 1,108 diagnostic statements were processed with an error rate of 9.3% for the latest version on the last 493 statements.
Collapse
|
3
|
Avramis VI, Panosyan EH, Avramis IA, Dorey F, Gaynon P. Pharmacodynamic relationships between asparagine INPUT (Imax) post asparaginase (ASNase) therapy and outcome in SR ALL patients (CCG-1962). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9025 Background: ASNase is an important agent in the treatment of childhood acute lymphoblastic leukemia. Most other chemotherapeutic agents require entry into cells and some variety of activation. ASNase acts unmodulated and totally outside of cells, targeting extracellular ASN and glutamine. Several investigators have described a relationship between ASNase activity and ASN. In vivo, the equilibrium asparagine level depends on the input rate of ASN derived from the nutrients plus the de novo biosynthesis minus its deamination from the serum ASNase activity. Imax is a pharmacodynamic (PD) parameter developed in 1980’s representing the cumulative input of ASN from nutrients and de novo biosynthesis. Of note, glutamine is the amino group source for the synthesis of ASN from aspartate. In Enzyme-substrate relationships a sigmoid relationship exists that reaches a maximum product formation (Imax). We reported a link between Day 14 ASN depletion - not ASNase activity - and response for children with ALL in first marrow relapse (Jarrar et al, 2006). Methods: On CCG-1962, 117 children with standard risk ALL were randomly allocated to native or pegylated ASNase. Relevant PK-PD parameters have been reported (Avramis et al, Blood 2002). ASNase activity was not predictive of EFS. Induction (IND) Day 3 - 24 serum ASN levels were fitted into a PD model and the Imax values were evaluated for 112 patients. Results: The median Imax values were 1E-6 nmoles/ml/min in all 112 (range 2.0E-2 to 1.0E-7) and in the native or PEG-ASNase randomized patients. The mean values were 1.1E-3.1±3E-3 in 112 patients and 1.5E-3±4.0E-3 & 1.1E-3±3.0E-3 nmoles/ml/min in the native or PEG-ASNase randomized patients. We examined EFS by Imax values in lifetable analyses. High Imax values predicted statistically poorer outcome (p<0.00001) with various cut-off values (e.g., Imax ≥1x 10−3 or Imax ≥5 × 10−4 nmoles/ml/min. The effect was similar in the native and pegylated ASNase subsets. ASNase activity was not prognostic. Conclusions: Hence, ASN Imax in serum is a treatment-independent PD prognostic factor in a subset of children with standard risk ALL. Strategies to provide uniform therapeutic effect among patients with differing Imax are under consideration. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | | | - F. Dorey
- Children’s Hospital of Los Angeles, Los Angeles, CA
| | - P. Gaynon
- Children’s Hospital of Los Angeles, Los Angeles, CA
| |
Collapse
|
4
|
Aricó M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T, Gadner H, Gaynon P, Horibe K, Hunger SP, Janka-Schaub G, Masera G, Nachman J, Pieters R, Schrappe M, Schmiegelow K, Valsecchi MG, Pui CH. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005. Leukemia 2005; 19:1145-52. [PMID: 15902295 DOI: 10.1038/sj.leu.2403783] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Between 1995 and 2004, six International Childhood Acute Lymphoblastic Leukemia (ALL) Workshop have been held, and the completion of several collaborative projects has established the clinical relevance and treatment options for several specific genetic subtypes of ALL. This meeting report summarizes the data presented in the seventh meeting and the discussion.
Collapse
Affiliation(s)
- M Aricó
- Associazione Italiana di Ematologia ed Oncologia Pediatrica, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Jeha S, Razzouk B, Gaynon P, Kadota R, Rheingold S, Luchtman-Jones L, Arceci R, Fernandez M, Weitman S, Steinherz P. Phase II trials of clofarabine in pediatric acute leukemia. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6588] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Jeha
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - B. Razzouk
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - P. Gaynon
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - R. Kadota
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - S. Rheingold
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - L. Luchtman-Jones
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - R. Arceci
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - M. Fernandez
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - S. Weitman
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - P. Steinherz
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| |
Collapse
|
6
|
Robison LL, Francisco L, Gaynon P, Sather H, Trigg M, Reaman G, Bleyer WA, Carroll W, Bhatia S. Late mortality after childhood acute lymphoblastic leukemia (ALL). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. L. Robison
- University of Minnesota, Minneapolis, MN; City of Hope National Medical Center, Duarte, CA; Childrens Hospital Los Angeles, Los Angeles, CA; Childrens Oncology Group, Arcadia, CA; AI duPont Inst, Wilmington, DE; Childrens Oncology Group, Bethesda, MD; M.D. Anderson Cancer Center, Houston, TX; Mount Sinai Medical Center, New York, NY
| | - L. Francisco
- University of Minnesota, Minneapolis, MN; City of Hope National Medical Center, Duarte, CA; Childrens Hospital Los Angeles, Los Angeles, CA; Childrens Oncology Group, Arcadia, CA; AI duPont Inst, Wilmington, DE; Childrens Oncology Group, Bethesda, MD; M.D. Anderson Cancer Center, Houston, TX; Mount Sinai Medical Center, New York, NY
| | - P. Gaynon
- University of Minnesota, Minneapolis, MN; City of Hope National Medical Center, Duarte, CA; Childrens Hospital Los Angeles, Los Angeles, CA; Childrens Oncology Group, Arcadia, CA; AI duPont Inst, Wilmington, DE; Childrens Oncology Group, Bethesda, MD; M.D. Anderson Cancer Center, Houston, TX; Mount Sinai Medical Center, New York, NY
| | - H. Sather
- University of Minnesota, Minneapolis, MN; City of Hope National Medical Center, Duarte, CA; Childrens Hospital Los Angeles, Los Angeles, CA; Childrens Oncology Group, Arcadia, CA; AI duPont Inst, Wilmington, DE; Childrens Oncology Group, Bethesda, MD; M.D. Anderson Cancer Center, Houston, TX; Mount Sinai Medical Center, New York, NY
| | - M. Trigg
- University of Minnesota, Minneapolis, MN; City of Hope National Medical Center, Duarte, CA; Childrens Hospital Los Angeles, Los Angeles, CA; Childrens Oncology Group, Arcadia, CA; AI duPont Inst, Wilmington, DE; Childrens Oncology Group, Bethesda, MD; M.D. Anderson Cancer Center, Houston, TX; Mount Sinai Medical Center, New York, NY
| | - G. Reaman
- University of Minnesota, Minneapolis, MN; City of Hope National Medical Center, Duarte, CA; Childrens Hospital Los Angeles, Los Angeles, CA; Childrens Oncology Group, Arcadia, CA; AI duPont Inst, Wilmington, DE; Childrens Oncology Group, Bethesda, MD; M.D. Anderson Cancer Center, Houston, TX; Mount Sinai Medical Center, New York, NY
| | - W. A. Bleyer
- University of Minnesota, Minneapolis, MN; City of Hope National Medical Center, Duarte, CA; Childrens Hospital Los Angeles, Los Angeles, CA; Childrens Oncology Group, Arcadia, CA; AI duPont Inst, Wilmington, DE; Childrens Oncology Group, Bethesda, MD; M.D. Anderson Cancer Center, Houston, TX; Mount Sinai Medical Center, New York, NY
| | - W. Carroll
- University of Minnesota, Minneapolis, MN; City of Hope National Medical Center, Duarte, CA; Childrens Hospital Los Angeles, Los Angeles, CA; Childrens Oncology Group, Arcadia, CA; AI duPont Inst, Wilmington, DE; Childrens Oncology Group, Bethesda, MD; M.D. Anderson Cancer Center, Houston, TX; Mount Sinai Medical Center, New York, NY
| | - S. Bhatia
- University of Minnesota, Minneapolis, MN; City of Hope National Medical Center, Duarte, CA; Childrens Hospital Los Angeles, Los Angeles, CA; Childrens Oncology Group, Arcadia, CA; AI duPont Inst, Wilmington, DE; Childrens Oncology Group, Bethesda, MD; M.D. Anderson Cancer Center, Houston, TX; Mount Sinai Medical Center, New York, NY
| |
Collapse
|
7
|
Jeha S, Razzouk B, Gaynon P, Kadota R, Rheingold S, Luchtman-Jones L, Arceci R, Fernandez M, Weitman S, Steinherz P. Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8504] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Jeha
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - B. Razzouk
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - P. Gaynon
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - R. Kadota
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Rheingold
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L. Luchtman-Jones
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - R. Arceci
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. Fernandez
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Weitman
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - P. Steinherz
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
8
|
Perentesis JP, Bhatia S, Boyle E, Shao Y, Shu XO, Steinbuch M, Sather HN, Gaynon P, Kiffmeyer W, Envall-Fox J, Robison LL. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia 2004; 18:685-92. [PMID: 14990973 DOI: 10.1038/sj.leu.2403272] [Citation(s) in RCA: 87] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Activating mutations in the RAS oncogenes are among the most common genetic alterations in human cancers, including patients with acute lymphoblastic leukemia (ALL). We sought to define the frequency and spectrum, and possible prognostic importance, of N- and K-RAS mutations in children with ALL treated with contemporary therapy. Leukemic blast DNA from 870 children was analyzed for the presence of activating mutations in the N- or K-RAS oncogenes using a sensitive mutation detection algorithm. RAS mutations were present in the blasts of 131 (15.1%) pediatric ALL patients. The spectrum of mutations included 81 (9.3%) mutations of codons 12/13 of N-RAS, 12 (1.4%) mutations of codon 61 of N-RAS, 39 (4.5%) mutations of codons 12/13 of K-RAS, and 2 (0.2%) mutations of codon 61 of K-RAS. The presence of N- or K-RAS mutations was not associated with white blood cell count at diagnosis, sex, race, extramedullary testicular involvement, central nervous system disease, or NCI/CTEP ALL Risk Group. Patients with an exon 1 K-RAS mutation (codons 12/13) were significantly younger at diagnosis (P=0.001) and less frequently B-lineage phenotype (P=0.01). RAS mutation status did not predict overall survival, event-free survival and disease-free survival. While N- and K-RAS mutations can be identified in 15% of children with newly diagnosed ALL, they do not represent a significant risk factor for outcome using contemporary chemotherapy regimens.
Collapse
Affiliation(s)
- J P Perentesis
- Children's Hospital Medical Center, Cincinnati, OH, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Pui CH, Schrappe M, Masera G, Nachman J, Gadner H, Eden OB, Evans WE, Gaynon P. Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia 2004; 18:1043-53. [PMID: 15085155 DOI: 10.1038/sj.leu.2403365] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- C-H Pui
- St Jude Children's Research Hospital, Memphis, TN, USA.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, Richards S. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 2003; 21:1798-809. [PMID: 12721257 DOI: 10.1200/jco.2003.08.047] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE A collaborative meta-analysis was performed to clarify the relative effects on relapse and survival of different types of therapies directed at the CNS in childhood acute lymphoblastic leukemia. MATERIALS AND METHODS Data were sought for each individual patient in all trials started in or before 1993 that included unconfounded randomized comparisons of such treatments. Log-rank survival analyses were performed for each trial, and overall results for groups of trials addressing similar questions were obtained from the totals of the observed minus expected number of events and their variances. RESULTS Radiotherapy and long-term intrathecal therapy gave similar outcomes, with no significant difference in event-free survival despite random assignment of treatment to 2,848 patients, 1,001 of whom suffered relapse or death. Intravenous methotrexate reduced non-CNS rather than CNS relapses, and hence, the addition of intravenous methotrexate to a treatment regimen including radiotherapy or long-term intrathecal therapy improved event-free survival, with a 17% reduction in the event rate (95% confidence interval, 6% to 27%; P =.003). The event-free survival at 10 years in these trials was 61.9% without intravenous methotrexate and 68.1% with intravenous methotrexate. There was no significant difference in survival (14% death rate reduction; P =.09). There were insufficient randomly assigned patients to adequately address other questions, such as effect of different doses. No evidence was found of differences, between trials or between subgroups of different types of patients, in the relative effects of treatment. CONCLUSION Radiotherapy can be replaced by long-term intrathecal therapy. Intravenous methotrexate gives some additional benefit by reducing non-CNS relapses.
Collapse
Affiliation(s)
- M Clarke
- Clinical Trial Service Unit, Radcliffe Infirmary, Oxford OX2 6HE, United Kingdom.
| | | | | | | | | | | | | |
Collapse
|
11
|
Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000; 14:2193-4. [PMID: 11187910 DOI: 10.1038/sj.leu.2401977] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
12
|
Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342:998-1006. [PMID: 10749961 DOI: 10.1056/nejm200004063421402] [Citation(s) in RCA: 384] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) have a poor prognosis, and there is no consensus on the optimal treatment for this variant of ALL. METHODS We reviewed the medical records of patients with Ph-positive ALL who were treated with intensive chemotherapy, with or without bone marrow transplantation, by 10 study groups or large single institutions from 1986 to 1996. Data on 326 children and young adults, who ranged in age from 0.4 to 19.9 years (median, 8.1), were analyzed to determine the rate of complete remission and the probability of event-free, disease-free and overall survival according to standard prognostic factors and type of treatment. RESULTS The 267 patients who achieved a complete remission after induction chemotherapy (82 percent) were stratified into three subgroups according to the age and leukocyte count at the time of diagnosis: those with the best prognosis (a leukocyte count of less than 50,000 per cubic millimeter and an age of less than 10 years; 95 patients); those with an intermediate prognosis (intermediate-risk features; 92 patients); and those with the worst prognosis (a leukocyte count of more than 100,000 per cubic millimeter; 80 patients). The estimates of disease-free survival at five years (+/-SE) were 49+/-5 percent) for patients with the best prognosis), 30+/-5 percent (for those with an intermediate prognosis), and 20+/-5 percent (for those with the worst prognosis) (P<0.001 for the overall comparison). We also found that transplantation of bone marrow from an HLA-matched related donor offered significantly greater benefit than intensive chemotherapy alone in terms of protecting patients from relapse or other adverse events (relative risk, 0.3; 95 percent confidence interval, 0.2 to 0.5; P<0.001). This finding was consistent in all three groups. CONCLUSIONS Unlike the usual type of all, Ph-positive ALL is associated with a poor prognosis. Nevertheless, in some patients with favorable prognosis features, the disease can be be controlled by intensive chemotherapy. Transplantation of bone marrow from an HLA-matched related donor is superior to other types of transplantation and to intensive chemotherapy alone in prolonging initial complete remissions.
Collapse
Affiliation(s)
- M Aricò
- Department of Pediatrics, Instituto Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Ek O, Gaynon P, Zeren T, Chelstrom LM, Myers DE, Uckun FM. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leuk Lymphoma 1998; 31:143-9. [PMID: 9720724 DOI: 10.3109/10428199809057594] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We have compared the antileukemic activity of the investigational biotherapeutic agent B43-PAP to the antileukemic activities of the standard chemotherapeutic drugs vincristine (VCR), methylprednisolone (PDN), L-asparaginase (L-ASP) as single agents as well as in a 3-drug combination regimen ("VPL") using a SCID mouse model of human B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). When mice (N = 95) were challenged with 1 x 10(6) NALM-6 leukemia cells, all of them died of disseminated leukemia with a median event-free survival (EFS) of 47 +/- 6 days. B43-PAP was more active than VCR, PDN, or L-ASP and the two-drug combinations VCR + B43-PAP, PDN + B43-PAP, or L-ASP + B43-PAP were not significantly more active than B43-PAP. The 120 days EFS outcome results were 46 +/- 13% for B43-PAP (Median EFS = 92 +/- 22 days), 0 +/- 0% for VCR (Median EFS = 49 +/- 1 days), 40 +/- 22% for PDN (Median EFS = 100 +/- 20 days), 0 +/- 0% for L-ASP (Median EFS = 41 +/- 1 days), 60 +/- 22% for VCR + B43-PAP (Median EFS = >120 days), 60 +/- 22% for PDN + B43-PAP (Median EFS = >120 days), and 50 +/- 25% for L-ASP + B43-PAP (Median EFS = 93 +/- 27 days), When mice (N = 61) were challenged with 5 x 10(6) NALM-6 cells, all of them rapidly died of disseminated leukemia with a median EFS of 37 +/- 3 days. The 3-drug combination "VPL" (Median EFS = 75 +/- 23 days) was slightly less active than B43-PAP (Median EFS = 84 +/- 19 days) (P = 0.09). Notably, the combination of "VPL" with B43-PAP (i.e., VPLB) resulted in 100% survival. By comparison, the combination of "VPL" with daunorubicin (i.e., VPLD) (Median EFS = 69 +/- 31 days) was not more active than VPL. To our knowledge, this preclinical study is the first to demonstrate the feasibility and superb antileukemic activity of immunochemotherapy using anti-CD19 immunotoxin in combination with the standard 3-drug combination "VPL" against BCP ALL.
Collapse
Affiliation(s)
- O Ek
- Biotherapy Program, University of Minnesota, Minneapolis, USA
| | | | | | | | | | | |
Collapse
|
14
|
Uckun FM, Sather H, Gaynon P, Arthur D, Nachman J, Sensel M, Steinherz P, Hutchinson R, Trigg M, Reaman G. Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma 1997; 27:445-57. [PMID: 9477126 DOI: 10.3109/10428199709058311] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Leukemic cells from most patients with B-lineage acute lymphoblastic leukemia (ALL) appear to originate from normal B-lymphocyte precursors. The earliest B-cell progenitors coexpress the antigens CD10, CD19, or CD34 on their cell surfaces. In a large cohort of 2028 children with ALL, we compared treatment outcomes of a subset of B-lineage ALL patients with CD10+CD19+CD34+ immature B-progenitor leukemia (BPL) to the treatment outcomes of the remaining CD19+ B-lineage ALL patients. Pediatric B-lineage ALL cases enrolled on risk-adjusted ALL treatment protocols of the Children's Cancer Group were immunophenotypically classified as BPL or non-BPL. Patients were stratified further into age groups of > or = 1 year and <12 months. Event-free survival (EFS) outcomes were calculated by standard life table methods. BPL patients in both age groups generally had more favorable presenting characteristics than non-BPL controls. Within the age group of > or = 1 year, BPL patients had a slightly better EFS outcome than non-BPL patients, with 3-year estimates of 83.9% (SD = 1.1%) vs. 78.8% (SD = 1.8%), respectively (P = 0.10). Infants with BPL, representing one-fifth of the total infant patient population, had a significantly better EFS outcome than infants with non-BPL (three-year EFS: 82.4%, SD = 9.2% vs. 34.4%, SD = 5.9%, P = 0.006). In univariate analyses, the relative hazard rate (RHR) was 3.73 for non-BPL vs BPL and this marked difference in EFS outcome was maintained at 5 years of follow-up. The favorable prognostic influence of the BPL immunophenotype for infants remained significant in multivariate analyses with an RHR of 2.72 for non-BPL vs BPL (P = 0.05). CD10+CD19+CD34+ immature B-progenitor immunophenotype is associated with favorable characteristics for children with ALL and identifies a subset of infants who achieve favorable EFS outcomes.
Collapse
Affiliation(s)
- F M Uckun
- Children's Cancer Group ALL Biology Reference Laboratory, and Biotherapy Institute, University of Minnesota Academic Health Center, Roseville, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Uckun FM, Yang Z, Sather H, Steinherz P, Nachman J, Bostrom B, Crotty L, Sarquis M, Ek O, Zeren T, Tubergen D, Reaman G, Gaynon P. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study. Blood 1997; 89:3769-77. [PMID: 9160683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
We found a marked variation in BCL-2 oncoprotein expression levels of primary leukemic cells from 338 children with newly diagnosed acute lymphoblastic leukemia (ALL). None of the high-risk features predictive of poor treatment outcome in childhood ALL, such as older age, high white blood cell (WBC) count, organomegaly, T-lineage immunophenotype, ability of leukemic cells to cause overt leukemia in severe combined immunodeficient (SCID) mice, presence of MLL-AF4, and BCR-ABL fusion transcripts were associated with high levels of BCL-2 expression. Overall, high BCL-2 levels were not associated with slow early response, failure to achieve complete remission, or poor event-free survival. High BCL-2 levels in primary leukemic cells predicted slow early response only in T-lineage ALL patients, which comprised approximately 15% of the total patient population. Even for this small subset of patients, the level of BCL-2 expression did not have a significant impact on the short-term event-free survival.
Collapse
MESH Headings
- Adolescent
- Adult
- Animals
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Apoptosis
- Biomarkers, Tumor
- Burkitt Lymphoma/genetics
- Burkitt Lymphoma/metabolism
- Burkitt Lymphoma/mortality
- Burkitt Lymphoma/pathology
- Child
- Child, Preschool
- Cohort Studies
- Disease-Free Survival
- Female
- Gene Expression Regulation, Leukemic
- Genes, bcl-2
- Humans
- Immunophenotyping
- Infant
- Leukemia-Lymphoma, Adult T-Cell/genetics
- Leukemia-Lymphoma, Adult T-Cell/metabolism
- Leukemia-Lymphoma, Adult T-Cell/mortality
- Leukemia-Lymphoma, Adult T-Cell/pathology
- Male
- Mice
- Mice, SCID
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Neoplasm Proteins/physiology
- Neoplasm Transplantation
- Oncogene Proteins, Fusion/analysis
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
- Prognosis
- Proto-Oncogene Proteins c-bcl-2/biosynthesis
- Proto-Oncogene Proteins c-bcl-2/genetics
- Proto-Oncogene Proteins c-bcl-2/physiology
- Remission Induction
- Risk Factors
- Survival Analysis
- Treatment Outcome
Collapse
Affiliation(s)
- F M Uckun
- Biotherapy Institute, University of Minnesota, Roseville 55113, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Uckun FM, Gaynon P, Sather H, Arthur D, Trigg M, Tubergen D, Nachman J, Steinherz P, Sensel MG, Reaman GR. Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 1997; 89:2488-93. [PMID: 9116293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Leukemic cells from a subset of children with acute lymphoblastic leukemia (ALL) express lymphoid antigens of both T lineage and B lineage, but the clinical significance of this immunophenotype is unknown. We now report the first comprehensive comparison of treatment outcomes among a large cohort of children with CD2+ CD19+ biphenotypic ALL (N = 77), B-lineage ALL (BL) (N = 1,631), or T-lineage ALL (TL) (N = 347) ALL who were treated on risk-adjusted Children's Cancer Group (CCG) protocols. CD2+ CD19+ patients were more similar to BL than TL patients with respect to presenting features and antigen expression. The percentages of patients achieving successful induction therapy outcome were 98.7%, 97.8%, and 97.3% for CD2+ CD19+, BL, and TL patients, respectively. Univariate comparisons of 4-year event-free survival (83.7%, 72.8%, 75.2% for CD2+ CD19+, BL, and TL patients, respectively) achieved borderline significance (CD2+ CD19+ B, P = .08; CD2+ CD19+ v T, P = .07). Relative hazard rate (RHR) estimates for BL and TL compared with CD2+ CD19+ were 1.79 and 1.90, respectively, implying a better outcome for biphenotypic patients. However, multivariate adjusted RHRs for BL and TL compared with CD2+ CD19+ were 1.43 (P = .29) and 1.16 (P = .76), respectively, suggesting a significant reduction in risk for BL or TL patients once adjustment was made for the more favorable characteristics of the CD2+ CD19+ group. Thus, pediatric ALL patients treated on contemporary CCG protocols who present with CD2+ CD19+ biphenotypic leukemia generally have good treatment outcomes, due in part to their favorable presenting features.
Collapse
MESH Headings
- Adolescent
- Antigens, CD19/analysis
- Antigens, Differentiation/analysis
- Antigens, Neoplasm/analysis
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- CD2 Antigens/analysis
- Child
- Child, Preschool
- Cohort Studies
- Disease-Free Survival
- Female
- Humans
- Infant
- Leukemia, B-Cell/drug therapy
- Leukemia, B-Cell/mortality
- Leukemia, B-Cell/pathology
- Leukemia, T-Cell/drug therapy
- Leukemia, T-Cell/mortality
- Leukemia, T-Cell/pathology
- Life Tables
- Male
- Neoplastic Stem Cells/immunology
- Phenotype
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
- Remission Induction
- Treatment Outcome
Collapse
Affiliation(s)
- F M Uckun
- Biotherapy Institute, University of Minnesota, Roseville 55113, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P, Reaman G. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 1996; 88:4288-95. [PMID: 8943865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
We examined the prognostic impact of CD2 antigen expression for 651 patients with T-lineage acute lymphoblastic leukemia (ALL), who were enrolled in front-line Childrens Cancer Group treatment studies between 1983 and 1994. There was a statistically significant correlation between the CD2 antigen positive leukemic cell content of bone marrow and probability of remaining in bone marrow remission, as well as overall event-free survival (EFS) (P = .0003 and P = .002, log-rank tests for linear trend). When compared with patients with the highest CD2 expression level (> 75% positivity), the life table relative event rate (RER) was 1.22 for patients with intermediate range CD2 expression level (30% to 75% positivity) and 1.81 for "CD2-negative" patients (< 30% positivity). At 6 years postdiagnosis, the EFS estimates for the three CD2 expression groups (low positivity to high positivity) were 52.8%, 65.5%, and 71.9%, respectively. CD2 expression remained a significant predictor of EFS after adjustment for the effects of other covariates by multivariate regression, with a RER of 1.47 for CD2-negative patients (P = .04). Analysis of T-lineage ALL patients shows a significant separation in EFS after adjustment for the National Cancer Institute (NCI) age and white blood cell (WBC) criteria for standard and high-risk ALL (P = .002, RER = 1.67). The determination of CD2 expression on leukemic cells helped identify patients with the better and poorer prognoses in both of these risk group subsets. For standard risk T-lineage ALL, CD2-negative patients had a worse outcome (P = .0007, RER = 2.92) with an estimated 5-year EFS of 55.9% as compared with 78.3% for the CD2-positive patients. Thus, CD2 negativity in standard risk T-lineage ALL identified a group of patients who had a worse outcome than high-risk T-lineage ALL patients who were CD2 positive. The percentage of CD2 antigen positive leukemic cells from T-lineage ALL patients is a powerful predictor of EFS after chemotherapy. This prognostic relationship is the first instance in which a biological marker in T-lineage ALL has been unequivocally linked to treatment outcome.
Collapse
Affiliation(s)
- F M Uckun
- Children's Cancer Group ALL Biology Reference Laboratory, University of Minnesota, Minneapolis 55113, USA
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Uckun FM, Reaman G, Steinherez PG, Arthur DC, Sather H, Trigg M, Tubergen D, Gaynon P. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. Leuk Lymphoma 1996; 24:57-70. [PMID: 9049962 DOI: 10.3109/10428199609045714] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The prognostic importance of T-lineage acute lymphoblastic leukemia (ALL) in contemporary programs of intensive chemotherapy has been controversial. We therefore assessed the impact of this biological feature in risk-adjusted frontline chemotherapy studies of the Children's Cancer Group (CCG), conducted from 1983 to 1994. A substantially greater proportion of T-lineage patients (N = 730) presented with poor-risk features as compared to B-lineage patients (N = 3668) treated in the same studies (71.1% vs. 39.7%, P < 0.0001). Consequently, in the CCG-100 series of clinical trials (1983-1989), which tested regimens that were largely of moderate intensity, T-lineage ALL patients had an excess of adverse early events compared to patients in the B-lineage group: 3-year event-free survival (EFS) estimate, 65.8% vs 78.2% (P < 0.0001). With the introduction of more intensive chemotherapy in studies from 1989 to 1994 (CCG-1800 series). We observed a progressive and significant improvement in the clinical outcome of patients with T-lineage immunophenotype. Three- and 5-year EFS probabilities increased from 65.8% to 78.1% and from 61.0% to 75.2%, respectively, becoming comparable to or slightly better than results for B-lineage ALL patients. When adjusted for the competing effects of leukocyte count, age, organomegaly and other poor-risk features, T-lineage immunophenotype showed no important impact on the overall EFS pattern. These findings demonstrate the loss of adverse prognostic by T-lineage ALL in a large program of intensive chemotherapy developed over the past decade.
Collapse
Affiliation(s)
- F M Uckun
- Children's Cancer Group ALL Biology Reference Laboratory, University of Minnesota, Minneapolis, USA
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Cherlow JM, Sather H, Steinherz P, Gaynon P, Tubergen D, Trigg M, Novak L, Bleyer WA. Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children's Cancer Group. Int J Radiat Oncol Biol Phys 1996; 36:19-27. [PMID: 8823255 DOI: 10.1016/s0360-3016(96)00272-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
PURPOSE This study attempted to determine if central nervous system (CNS) disease at diagnosis is a poor prognostic factor in children with acute lymphoblastic leukemia (ALL) and whether 6 Gy of spinal irradiation is an adequate dose for these patients. METHODS AND MATERIALS Previously the Children's Cancer Group (CCG) treated patients with ALL and CNS disease at diagnosis with cranio (24 Gy)-spinal (12 Gy) irradiation, as well as systemic and intrathecal chemotherapy. In a series of CCG trials completed in 1989 the spinal dose was empirically reduced to 6 Gy for patients receiving systemic chemotherapy with an intensive consolidation phase to limit hematopoietic toxicity. The spinal dose was left at 12 Gy for patients treated with a less intensive consolidation phase. RESULTS With a median follow-up for surviving patients of 74 months, the 5-year event-free survival for 53 patients with CNS disease at diagnosis was 69 +/- 13% (+/- 2 standard deviations), similar to the value obtained for 3364 patients without CNS disease, 67 +/- 2%. Corresponding values for 5-year survival were 77 +/- 12% and 80 +/- 1%, and for freedom from isolated first CNS relapse, were 90 +/- 9% and 94 +/- 1%. Event-free survival, survival, and freedom from isolated first CNS relapse in the 6-Gy group were as good as in the 12-Gy group. CONCLUSION CNS disease at diagnosis is not a poor prognostic factor for children with ALL who are treated with intensive systemic chemotherapy, craniospinal irradiation, and intrathecal chemotherapy. Six Gy is an adequate dose of spinal irradiation for these patients.
Collapse
Affiliation(s)
- J M Cherlow
- Radiation Oncology, Long Beach Memorial Medical Center, CA, USA
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14:18-24. [PMID: 8558195 DOI: 10.1200/jco.1996.14.1.18] [Citation(s) in RCA: 617] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
PURPOSE To define more uniform criteria for risk-based treatment assignment for children with acute lymphoblastic leukemia (ALL), the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) sponsored a workshop in September 1993. Participants included representatives from the Childrens Cancer Group (CCG), Pediatric Oncology Group (POG), Dana-Farber Cancer Institute (DFCI), St Jude Children's Research Hospital (SJCRH), and the CTEP. METHODS Workshop participants presented and reviewed data from ALL clinical trials, using weighted averages to combine outcome data from different groups. RESULTS For patients with B-precursor (ie, non-T, non-B) ALL, the standard-risk category (4-year event-free survival [EFS] rate, approximately 80%) will include patients 1 to 9 years of age with a WBC count at diagnosis less than 50,000/microL. The remaining patients will be classified as having high-risk ALL (4-year EFS rate, approximately 65%). For patients with T-cell ALL, different treatment strategies have yielded different conclusions concerning the prognostic significance of T-cell immunophenotype. Therefore, some groups/institutions will classify patients with T-cell ALL as high risk, while others will assign risk for patients with T-cell ALL based on the uniform age/WBC count criteria. Workshop participants agreed that the risk category of a patient may be modified by prognostic factors in addition to age and WBC count criteria, and that a common set of prognostic factors should be uniformly obtained, including DNA index (DI), cytogenetics, early response to treatment (eg, day-14 bone marrow), immunophenotype, and CNS status. CONCLUSIONS The more uniform approach to risk-based treatment assignment and to collection of specific prognostic factors should increase the efficiency of future ALL clinical research.
Collapse
Affiliation(s)
- M Smith
- Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Uckun FM, Sather H, Reaman G, Shuster J, Land V, Trigg M, Gunther R, Chelstrom L, Bleyer A, Gaynon P. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood 1995; 85:873-8. [PMID: 7849309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Mice with severe combined immunodeficiency (SCID) provide a model system to examine the in vivo homing, engraftment, and growth patterns of normal and malignant human hematopoietic cells. The relation between leukemic cell growth in this model and the treatment outcome in patients from whom cells were derived has not been established. Leukemic cells from 42 children with newly diagnosed high-risk B-lineage acute lymphoblastic leukemia were inoculated intravenously into CB.17 SCID mice. Mice were killed at 12 weeks or when they became moribund as a result of disseminated leukemia. All mice were necropsied and subjected to a series of laboratory studies to assess their burden of human leukemic cells. Twenty-three patients whose leukemic cells caused histopathologically detectable leukemia in SCID mice had a significantly higher relapse rate than the 19 patients whose leukemic cells did not (estimated 5-year event-free survival: 29.5% v 94.7%; 95% confidence intervals, 11.2% to 50.7% v 68.1% to 99.2%; P < .0001 by log-rank test). The occurrence of overt leukemia in SCID mice was was a highly significant predictor of patient relapse. The estimated instantaneous risk of relapse for patients whose leukemic cells caused overt leukemia in SCID mice was 21.5-fold greater than that for the remaining patients. Thus, growth of human leukemic cells in SCID mice is a strong and independent predictor of relapse in patients with newly diagnosed high-risk B-lineage acute lymphoblastic leukemia.
Collapse
Affiliation(s)
- F M Uckun
- University of Minnesota Biotherapy Program, the Department of Therapeutic Radiology, Minneapolis
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Kowal-Vern A, Johnson FL, Trujillo Y, Nachman J, Radhakrishnan J, Conard P, Gaynon P. Granulocytic sarcoma of the ileum treated by bone marrow transplantation. Am J Pediatr Hematol Oncol 1991; 13:34-8. [PMID: 2029076 DOI: 10.1097/00043426-199121000-00008] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
An 8-year-old boy with a granulocytic sarcoma of the proximal ileum metastatic to mesenteric lymph nodes was placed into complete remission with surgical excision of the primary tumor and conventional induction chemotherapy with daunorubicin and cytosine arabinoside. He was then treated with high dose cytosine arabinoside, fractionated total body irradiation, and allogeneic marrow transplantation from his 22-month-old brother who was completely matched at the major histocompatibility complex. Methotrexate was given following the transplant to prevent graft-versus-host disease (GVHD). His post-transplantation course was complicated by a transient autoimmune hemolytic anemia related to an ABO blood group incompatibility and hepatic fungal microabscesses which responded to Amphotericin therapy. Four years following the transplant the patient remains in complete remission. The prognosis for patients with granulocytic sarcoma has been poor although, perhaps, improved over the past decade. This is the first published case report of successful treatment of a granulocytic sarcoma of the ileum by allogeneic marrow transplantation.
Collapse
Affiliation(s)
- A Kowal-Vern
- Loyola University Medical Center, Maywood, Illinois 60153
| | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
Adults and children with brain stem gliomas have a mean survival time of 15 months after radiation therapy (XRT). Infants with this tumor present additional complexities for treatment because of possible neurotoxicity of the radiation to the developing brain. We report a 15-month-old child with biopsy-proven brain stem glioma with clinical and radiographic evidence of disease progression. She was treated with 24 monthly courses of carboplatin without radiation therapy and has had a 39+ month response. The clinical response started after 3 months and the radiographic evidence was documented at 10 months by magnetic resonance imaging. The toxicity was minimal. Longitudinal neuropsychological assessment demonstrated continued improvement at 36 months post diagnosis but with some motor functioning below expected age levels. Cervico-medullary astrocytoma in a young patient may be the appropriate clinical setting for future trials of chemotherapy without XRT.
Collapse
Affiliation(s)
- P M Zeltzer
- Department of Hematology/Oncology, Children's Hospital of Los Angeles, CA 90054-0700
| | | | | | | | | |
Collapse
|
24
|
Cherlow J, Steinherz P, Sather H, Gaynon P, Grossman N, Kersey J, Maurer H, Brenneman J, Trigg M, Hammond D. The role of radiation therapy in the management of acute lymphoblastic leukemia with lymphomatous presentation (ALL/LP). Int J Radiat Oncol Biol Phys 1990. [DOI: 10.1016/0360-3016(90)90750-e] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Steinherz PG, Gaynon P, Miller DR, Reaman G, Bleyer A, Finklestein J, Evans RG, Meyers P, Steinherz LJ, Sather H. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. J Clin Oncol 1986; 4:744-52. [PMID: 3517244 DOI: 10.1200/jco.1986.4.5.744] [Citation(s) in RCA: 127] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
An intensive multimodal therapy was developed for the treatment of a subpopulation of children with acute lymphoblastic leukemia (ALL) who had a predicted event-free survival of less than 40% on previously reported therapeutic regimens (at high risk for early relapse). Induction with multiagent chemotherapy and radiotherapy to bulky disease-bearing areas (peripheral lymph nodes and mediastinum) was followed by consolidation, CNS prophylaxis, and cyclical remission maintenance therapy. Ninety-six (96%) of 100 previously untreated patients, 1 to 17 years of age, attained a complete remission. Seven patients received other maintenance therapy or a bone marrow transplant in remission. Sixty-six of the remaining 89 (74%) are in continuous complete remission at 22+ to 72+ months (median, 44+ months). Marrow relapse occurred in 15 (17%), CNS relapse in 5 (6%), and testicular relapse in one. Sixty-six of the 93 evaluable patients (71%) (including the induction failures) are event-free survivors. Two patients died of infection during the induction phase. No patient died during consolidation or maintenance without recurrent disease. The patients spent a median of 19, 0, and 0 days hospitalized during induction, consolidation, and maintenance, respectively. The most common complications were bacteremia and mucositis during induction and mucositis and fever during periods of neutropenia in consolidation. Maintenance was well tolerated. We conclude that the treatment protocol is intensive, but the inherent toxicities are manageable with adequate supportive care. The life table--projected event-free survival of 69% +/- 5% 48 months from diagnosis is encouraging.
Collapse
|
26
|
Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Cancer Treat Rep 1981; 65:815-22. [PMID: 6944156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
A total of 114 children with solid tumors refractory to conventional therapy were evaluated for response and/or toxic effects after receiving cisplatin at doses of 3.0-4.5 mg/kg with aggressive hydration and mannitol diuresis every 3 weeks; a minimum of two courses was required for evaluation of response (110 patients). Objective responses were noted in 18 patients: rhabdomyosarcoma (three), Wilm's tumor (three), osteogenic sarcoma (three). Ewing's sarcoma (two), neuroblastoma (one), undifferentiated sarcoma (one), hepatoblastoma (one), ovarian teratoma (one), hepatocellular carcinoma (one), embryonal carcinoma of the mediastinum (one), and thymoma (one). Twenty-six patients had some evidence of renal toxicity. Asymptomatic hearing loss was commonly found when audiometry was performed (eight of 18 patients tested). Eight additional patients had symptomatic hearing problems--tinnitus or hearing loss. Myelosuppression was mild. Hypomagnesemia and/or hypocalcemia were common but only one patient had symptoms. Cisplatin, administered at a dose of 3.0 mg/kg with aggressive hydration and mannitol diuresis, is reasonably well-tolerated. Its role in the therapy for those tumors against which it shows activity remains to be determined.
Collapse
|
27
|
Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report. Cancer Treat Rep 1979; 63:1621-7. [PMID: 291484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
28
|
Gaynon P, Honig GR. A computer-based system for management of clinical and laboratory data of a comprehensive sickle cell center. Methods Inf Med 1974; 13:216. [PMID: 4437396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
29
|
Gaynon P, Wong RL. A retrieval system for a library of pathology reports, slides and kodachromes. Methods Inf Med 1972; 11:152-62. [PMID: 4114655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
30
|
Wong RL, Gaynon P. An automated parsing routine for diagnostic statements of surgical pathology reports. Methods Inf Med 1971; 10:168-75. [PMID: 4937156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|